Prioritizing Mental Health in the HIV/AIDS Response in Africa | NEJM
Perspective from The New England Journal of Medicine — Prioritizing Mental Health in the HIV/AIDS Response in Africa
Perspective from The New England Journal of Medicine — Prioritizing Mental Health in the HIV/AIDS Response in Africa
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
A 47-year-old man presented with 2-day history of weakness and fever. Laboratory studies showed pancytopenia. A bone marrow biopsy showed promyelocytes with abundant intracellular rods.
Most moderate-to-late–preterm infants need nutritional support until they are feeding exclusively on their mother’s breast milk. Evidence to guide nutrition strategies for these infants is…
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
A 57-year-old woman presented with a 3-day history of shortness of breath and dizziness. Laboratory studies showed severe anemia with hemolysis, along with cellular abnormalities…
Audio Interview from the New England Journal of Medicine — Interview with Kevin Schulman on unionization as a response to consolidation and corporatization in health…
We in the global malaria community are at a critical juncture in our journey toward malaria eradication. Decades of experience in deploying our existing interventions…
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…